Bruker (NASDAQ:BRKR) Releases FY 2026 Earnings Guidance

Bruker (NASDAQ:BRKR) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 2.100-2.150 for the period, compared to the consensus EPS estimate of 2.120. The company issued revenue guidance of $3.6 billion-$3.6 billion, compared to the consensus revenue estimate of $3.6 billion.

Analyst Ratings Changes

Several equities analysts have commented on the company. Citigroup cut their price target on Bruker from $53.00 to $40.00 and set a “neutral” rating for the company in a report on Friday, February 13th. UBS Group reaffirmed a “neutral” rating and issued a $49.00 price target on shares of Bruker in a report on Friday, February 13th. Weiss Ratings raised Bruker from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, April 24th. TD Cowen raised Bruker to a “hold” rating in a report on Monday, April 13th. Finally, The Goldman Sachs Group cut their price target on Bruker from $40.00 to $35.00 and set a “sell” rating for the company in a report on Friday, February 13th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Bruker presently has an average rating of “Hold” and an average target price of $49.38.

Bruker Trading Up 4.5%

Bruker stock opened at $38.01 on Wednesday. The business has a 50 day moving average price of $37.13 and a two-hundred day moving average price of $41.99. The company has a quick ratio of 0.87, a current ratio of 1.73 and a debt-to-equity ratio of 0.75. The stock has a market cap of $5.79 billion, a price-to-earnings ratio of -253.40, a price-to-earnings-growth ratio of 2.18 and a beta of 1.12. Bruker has a 12 month low of $28.53 and a 12 month high of $56.22.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.08. Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The company had revenue of $823.40 million for the quarter, compared to analyst estimates of $796.11 million. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities analysts forecast that Bruker will post 2.12 EPS for the current year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Stockholders of record on Monday, March 23rd were paid a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. The ex-dividend date was Monday, March 23rd. Bruker’s dividend payout ratio is currently -133.33%.

Insider Buying and Selling at Bruker

In other news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total value of $79,800.00. Following the sale, the vice president directly owned 128,443 shares in the company, valued at approximately $5,124,875.70. This represents a 1.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 27.20% of the company’s stock.

Institutional Investors Weigh In On Bruker

Large investors have recently bought and sold shares of the business. Sivia Capital Partners LLC bought a new stake in Bruker during the 2nd quarter worth approximately $297,000. Banco Bilbao Vizcaya Argentaria S.A. bought a new stake in Bruker during the 4th quarter worth approximately $224,000. iSAM Funds UK Ltd bought a new stake in Bruker during the 2nd quarter worth approximately $217,000. CIBC Asset Management Inc bought a new stake in Bruker during the 4th quarter worth approximately $203,000. Finally, Twin Tree Management LP grew its position in Bruker by 195.0% during the 3rd quarter. Twin Tree Management LP now owns 5,616 shares of the medical research company’s stock worth $182,000 after acquiring an additional 11,528 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.